Biolegend, 329714, Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1) Antibody, 100tests

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.
100tests
Verified Reactivity: Human
Reported Reactivity: African Green, Baboon, Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Full length human PD-L1
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest. Clone 29E.2A3 does not work in Western blot applications7.
Application References(PubMed link indicates BioLegend citation): Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block) Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block) Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block) Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed Haile, S et al. 2013. J. Immunol. 191:2829. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations: Saitoski K, et al. 2022. J Biol Chem. 298:102096. PubMed Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed Kiritsy MC, et al. 2021. Elife. 10:. PubMed Shenoy GN, et al. 2021. Clin Transl Immunology. 10:e1246. PubMed Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed Mohan N, et al. 2022. Front Immunol. 13:918528. PubMed Ferrando–Martinez S, et al. 2019. JHEP Rep. 0.159722222. PubMed Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed Hunter S, et al. 2018. J Hepatol. 69:654. PubMed Singh S, et al. 2022. Int J Mol Sci. 23:. PubMed Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed Chakravorty S, et al. 2019. Cancer Res. 79:6010. PubMed Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed Roybal KT et al. 2016. Cell. 167(2):419-432 . PubMed AlHossiny M, et al. 2016. Cancer Res . 76: 3376 - 3386. PubMed Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed Kiritsy MC, et al. 2021. Elife. 10:. PubMed Maurer DM, et al. 2020. Cancer Immunol Res. 8:1554. PubMed Hu Q, et al. 2021. Nat Biomed Eng. 5:1038. PubMed
RRID: AB_10901164 (BioLegend Cat. No. 329713) AB_2563852 (BioLegend Cat. No. 329714)
Distribution: T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells
Function: CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor: PD-1 (PDCD1)
Cell Type: B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area: Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family: Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
Gene ID: 29126
UniProt: View information about CD274 on UniProt.org
Clone: 29E.2A3
Regulatory Status: RUO
Other Names: Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype: Mouse IgG2b, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.